The majority of patients had the classic CD4+/CD8- CD25+ ATLL immunophenotype (83%), while fewer had an atypical phenotype (CD4+/CD8+ or CD4-/CD8-) (17%). This evidence concerns the gene CD8A and adult T-cell leukemia/lymphoma.